Back to News
Market Impact: 0.35
NeoGenomics, Inc. Reports Third Quarter 2026 Total Revenue of $209 million
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
NeoGenomics reported third-quarter 2026 revenue of $209 million, up 11% year over year. Clinical revenue rose 13% to $195 million, led by 29% growth in NGS; the article also states GAAP gross margin expanded by 3, but the reported figure is cut off.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
NEO0.65
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- Warren urges DOJ criminal probe of Bank of America over anti-money-laundering violations
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Quartr Alternatives for Institutional Research Teams